Journal article

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus

Rachel Koelmeyer, Hieu Tri Nim, Mandana Nikpour, Ying B Sun, Amy Kao, Oliver Guenther, Eric Morand, Alberta Hoi

Lupus Science & Medicine | BMJ PUBLISHING GROUP | Published : 2020


OBJECTIVE: Disease severity in SLE is an important concept related to disease activity, treatment burden and prognosis. We set out to evaluate if high disease activity status (HDAS), based on ever attainment of a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) disease activity score of ≥10, is an indicator for disease severity in SLE. METHODS: Using prospectively collected data, we assessed the association of HDAS with sociodemographic and disease characteristics and adverse clinical outcomes using logistic regression or generalised estimating equations. RESULTS: Of 286 patients with SLE, who were observed for a median (range) of 5.1 years (1-10.8 years), 43.7% experienced HDAS ..

View full abstract


Funding Acknowledgements

This study was funded by Merck Healthcare KGaA (Part sponsorship). Conduct of the Australian Lupus Registry and Biobank at the Monash Lupus Clinic and related analyses have been supported by unrestricted grants from Merck KGaA, GlaxoSmithKline, UCB, and Astra Zeneca. Merck KGaA in particular provided financial support for this study. MN is supported by an NHMRC Career Development Fellowship.